John Libbey Eurotext

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement


Frailty phenotype in older people living with HIV: concepts, prevention and issues Volume 17, issue 2, Juin 2019


1 Institut SIlvermed, Centre gérontologique départemental, Marseille, France
2 Unité de soins et de recherche en médecine interne, Hôpital européen, Marseille, France
3 Visage Study Group, COREVIH, Hôpital de la Conception, Marseille, France
4 Médecine interne, gériatrique et thérapeutique, CHU Sainte Marguerite, Assistance Publique, Marseille, France
5 Pharmacie hospitalière, CHU la Conception, Marseille, France
6 Service de Gériatrie, CHU de Nantes, Nantes, France
7 Pôle gériatrique, Centre gérontologique départemental, Marseille, France
8 Institut hospitalo-universitaire (IHU) méditerranée infection et maladies tropicales, Marseille, France
9 Centre d’étude et de recherche sur les services de santé et la qualité de vie, EA 3279, Aix Marseille Université, Marseille, France
* Correspondance

The life-span of people aging with HIV (PHIV) tends to reach people without infection, reflecting the effectiveness and tolerance of antiretroviral treatment and improvement of multidisciplinary management. Comorbidities or HIV-inflammaging seems to be the main determinants of frailty phenotype in PHIV. Prevalence of frailty in PHIV is frequent (5% from 28%) and appears earlier than in general population (50 versus 65 years). Almost half of people with HIV present prefrail phenotype before 50 years. The usefulness of integrate routinely measures of frailty phenotype is not yet known but several data are encouraging in terms of feasibility and prediction. Early determination of frailty in PHIV could lead to target interventions to improve global health and decrease adverse outcomes such as incapacities and early death.